Amgen Inc. discovers, develops, manufactures and commercializes prescription biologic and small‑molecule medicines across multiple therapeutic areas, operating as a single segment (human therapeutics). The company’s business model combines in-house R&D and biologics manufacturing with global commercialization, with product demand shaped by regulatory approvals and payer reimbursement. Amgen sells primarily through pharmaceutical wholesalers in the U.S. and through a mix of wholesalers and direct-to-provider channels internationally, supported by collaborations in certain markets. Its portfolio includes established brands (e.g., Prolia, Repatha, ENBREL) alongside newer growth products and a pipeline that targets high unmet medical need.
38,8 %
67,2 %
21,0 %
+10,0 %
1.14
0.90
| % | |
|---|---|
| General medicine (cardiometabolic, bone health, inflammation) | 55% Primary care and specialty medicines including bone health, lipid management and immunology/inflammation brands. |
| Oncology and hematology | 25% Cancer and blood-disorder therapies sold through oncology/hematology channels and hospitals. |
| Rare disease and specialty | 15% Specialty and rare-disease products often requiring specialist prescribing and payer authorization. |
| Other revenues (collaboration/partner and other) | 5% Non-product revenues such as collaboration-related income and other ancillary items. |
Amgen’s end customers are healthcare providers and patients, but its direct customers in the U.S...
Purchase large volumes for downstream distribution; central to U.S. channel access and working-capital dynamics.
Determine coverage, reimbursement and patient access; negotiate rebates/discounts that drive net price.
Prescribe and administer therapies (especially oncology and infused/injectable products) and influence product adoption.
Buy products under country-specific distribution models; growth depends on local access and partner execution.
Co-commercialize or commercialize in specific territories/products (e.g., TEZSPIRE ex-U.S.), affecting reach and economics.
Amgen markets products globally with a presence in approximately 100 countries, but product sales are concentrated in...
Amgen’s strategy centers on investing in innovation (internal R&D and external business development) while scaling...
Biologics supply reliability underpins revenue and launch execution; site concentration heightens the need for resilience.
Label expansions and new indications can extend product life and increase volume without full new-product risk.
Biopharma revenue durability depends on replenishing products facing competition and pricing pressure.
Amgen’s revenue is exposed to payer coverage and reimbursement decisions, with pricing pressure amplified by...
A substantial majority of commercial manufacturing is in Puerto Rico and clinical manufacturing in Thousand Oaks; disruptions could impair supply and trials.
Government and commercial payers influence access and net price; PBM consolidation increases negotiating leverage and risk of exclusion.
McKesson, Cencora and Cardinal Health each exceed 10% of revenues; combined ~77% of worldwide gross revenues, increasing bargaining power and credit exposure.
Certain raw materials, devices and components are proprietary to unaffiliated suppliers; shortages/quality issues can constrain production.
Supplier breaches have occurred with unauthorized access/exfiltration; delayed or incomplete incident reporting can impair response and increase impact.
AMRX · Pharmaceutical Preparations
Amneal Pharmaceuticals is a U.S.-based diversified biopharmaceutical company that develops, manufactures, markets, and distributes essential medicines across…
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
CI · Hospital & Medical Service Plans
Cigna Group is a U.S.-based global health company that combines health benefits and pharmacy/medical services through two core segments: Cigna Healthcare and Evernorth Health Services.
INGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Inogen Inc designs, markets, and sells portable and stationary oxygen concentrators and related respiratory products for people needing long-term oxygen therapy.
PFE · Pharmaceutical Preparations
COR · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cencora is a pharmaceutical sourcing and distribution company that sits between drug manufacturers and healthcare providers, moving branded, specialty,…
: 11/08/2026